Journal: Brain research bulletin
Article Title: Role of BDNF-TrkB signaling in the improvement of motor function and neuroplasticity after ischemic stroke in rats by transcranial direct current stimulation.
doi: 10.1016/j.brainresbull.2024.111164
Figure Lengend Snippet: Fig. 4. Effects of tDCS application on activation of PLCγ / CaMK IV / CREB and ERK1/2 / RSK signaling cascade following MCAO/R. (A) Plasma BDNF levels of patients. T test was used for statistical analysis. (B) Tricolor fluorescent labeling BDNF, NeuN, and DAPI, to observe the ischaemic semi-dark band in the infarcted region of the left cerebral cortex. Representative Western bands were normalised to the corresponding total protein levels and to GAPDH as a control, (C) Quan tification of the relative protein levels of PLCγ1, CaMK IV and CREB1 in three groups. The original images of the Western blot bands are available in the supple mentary material. (D) PLCγ1 expression,(E) CaMK IV expression, and (F) CREB1 expression in different groups. (G) Representative Western bands were normalised to the corresponding total protein levels and to GAPDH as a control. Quantification of the relative proteins levels of P-ERK, ERK and RSK in three groups. The original images of the Western blot bands are available in the supplementary material.(H) P-ERK1/2 / ERK1/2 expression and (I) RSK expression in different groups. The data are presented as means ± SEM. *p < 0.05,* *p < 0.01 vs. MCAO/R group. Differences between the groups were analyzed using one-way ANOVA followed by Tukey’s post hoc test. Different coloured bars represent different subgroups, and the vertical values show the ratio of the expression of the relevant proteins to the expression of the corresponding internal reference proteins.
Article Snippet: Then membranes were incubated using primary antibodies: anti- PLCγ (1:1000, Proteintech China), anti-CERB (1:1000 Cell Signaling Technology, US), anti-CaMK IV (1:1000, Abcam, UK), anti-RSK (1:1000, Cell Signaling Technology, US), anti-P-ERK1/2 (1:1000, Cell Signaling Technology, US), anti-ERK1/2 (1:1000, Cell Signaling Technology, US), anti-GAP 43 (1:1000, Abcam, UK) and anti-MAP 2 (1:1000, Abcam, UK) at 4◦C overnight.
Techniques: Activation Assay, Clinical Proteomics, Labeling, Western Blot, Control, Expressing